ORAI1 and renal cell adenocarcinoma: Several types of cancer, including cc-RCC, have been studied in phase I–III clinical trials that looked at how to block Orai1 with carboxyamidotriazole, a drug that targets both vascular endothelial cells and tumor-derived ECFC (120, 121).